Trial intelligence / Profile preview

Phase II preoperative pegylated liposomal doxorubicin in elderly patients with locally advanced breast cancer

2005-005039-86Phase 2Completed

Sponsor: European Institute of Oncology
Start: Feb 2006
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of doxorubicin in breast cancer, sponsored by European Institute of Oncology. Primary endpoints: Clinical response rate and Pathological complete remission. Started Feb 2006; status: completed.

Drugs

doxorubicin

Conditions

breast cancer

Beyond the preview

Go deeper on 2005-005039-86.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005039-86.